Company news

NovoCure Limited news in 2026

NovoCure Limited's news releases, calls and decks from 2026, newest first.

View company

Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

October 29, 2026

Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement

October 28, 2026

Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

October 1, 2026

Novocure to Report Third Quarter 2026 Financial Results

October 1, 2026

Novocure Reports Second Quarter 2026 Financial Results

July 23, 2026

Novocure to Report Second Quarter 2026 Financial Results

July 1, 2026

Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

June 30, 2026

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

June 18, 2026

Novocure Reports First Quarter 2026 Financial Results

April 30, 2026

Novocure to Report First Quarter 2026 Financial Results

March 31, 2026

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

March 25, 2026

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

March 1, 2026

Novocure to Participate in 2026 Leerink Global Healthcare Conference

February 27, 2026

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

February 25, 2026

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

February 23, 2026

U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

February 11, 2026

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

January 11, 2026

Calls in 2026

Decks in 2026